Improving the internal medical care to set up a leading model for precision medicine development in lung cancer / 中华肿瘤杂志

ABSTRACT

Lung cancer still remains the leading cause of cancer-related death worldwide. Recent development of molecular targeted therapies, especially the emergence of epidermal growth factor receptor (EGFR) inhibitors, has made an enormous progress for the treatment of non-small cell lung cancer (NSCLC). However, targeted therapy still faces many problems including acquired resistance. Several clinical trials have proved that targeted therapy can significantly improve the progression-free survival (PFS), but there are still many things needed to be improved. Thus, oncologists still have a long way to go for realizing precision medicine. The present article illustrates the impact of precision medicine on the treatment of lung cancer and describes how to improve the treatment level of lung cancer, aiming to give an inspiration to the medical oncologists.